Business
Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
Bioasis to Present at the 20th Annual BIO CEO & Investor Conference.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that \n it will present at the 20th Annual BIO CEO & Investor \n Conference, to be held February 12-13, 2018 at the New York Marriott \n Marquis.\n \n \n Mark Day, Ph.D., president and chief executive officer, Bioasis, will \n present at the BIO CEO & Investor Conference as follows:\n \n \n Date: Mon., Feb. 12, 2018\n \n \n Time: 3:15 p.m. ET\n \n \n Room: Odets Room (4th Floor)\n \n \n Venue: New York Marriott Marquis, 1535 Broadway, New York, NY \n 10036 (United States)\n \n \n About Bioasis\n \n \n Bioasis Technologies, Inc. is a preclinical biopharmaceutical company \n focused on the delivery of therapeutics across the blood-brain barrier \n (BBB) and into the central nervous system for the treatment of \n neurological diseases and disorders. The delivery of therapeutics across \n the BBB represents the single greatest challenge in treating \n neurological disorders. The company is developing and commercializing \n the xB3 platform, Bioasis’ proprietary blood-brain barrier delivery \n technology, to address unmet medical needs in the treatment of central \n nervous system diseases and disorders. The company maintains \n headquarters in Vancouver, Canada with offices in Guilford, Conn., \n United States. Bioasis trades on the TSX Venture Exchange under the \n symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more \n information about the company please visit www.bioasis.ca or www.bioasis.us.\n \n \n About the 2018 BIO CEO & Investor Conference\n \n \n The 2018 BIO CEO & Investor Conference is one of the largest investor \n conferences focused on established and emerging publicly traded and \n select private biotech companies. The conference, now in its 20th \n year, provides a forum where institutional investors, industry analysts, \n and senior biotechnology executives have the opportunity to shape the \n future investment landscape of the biotechnology industry.\n \n \n About BIO\n \n \n BIO is the world's largest trade association representing biotechnology \n companies, academic institutions, state biotechnology centers and \n related organizations across the United States and in more than 30 other \n nations. BIO members are involved in the research and ...